Paradigms for primary prevention of ovarian carcinoma

被引:30
作者
Barnes, MN [1 ]
Grizzle, WE
Grubbs, CJ
Partridge, EE
机构
[1] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA
关键词
D O I
10.3322/canjclin.52.4.216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To provide the clinician with current concepts regarding prevention of ovarian cancer. Specifically, in this review, we provide a rationale for chemoprevention of ovarian cancer, a description of promising chemopreventive agents, and an overview of surgical strategies used in the prevention of ovarian cancer. Data Sources: A computerized search of articles published through December 2001 was performed using the MEDLINE database from the period of 1966 to present. Search terms utilized included ovarian neoplasms, primary prevention, chemoprevention, oral contraceptives, NSAIDs, retinoids, ovariectomy, and tuba] sterilization. Additional sources were identified through cross-referencing, Methods of Study Selection: All identified references relevant to prevention of ovarian carcinoma were reviewed. Tabulation, Integration, and Results: Each reference was reviewed to determine the relevant contribution to the fundamental science of ovarian cancer prevention. Particular attention was paid to those studies that offered insight into the development of translational trials in ova an cancer chemoprevention. Conclusions: Investigation into chemoprevention for ovarian cancer represents a vastly underdeveloped area of research. Continued research efforts toward identification of novel compounds will accelerate the progress of clinical trials in this neglected area of investigation.
引用
收藏
页码:216 / 225
页数:10
相关论文
共 79 条
  • [1] Colon cancer prevention by NSAIDs: What is the mechanism of action?
    Ahnen, DJ
    [J]. EUROPEAN JOURNAL OF SURGERY, 1998, 164 : 111 - 114
  • [2] Non-steroidal anti-inflammatory drugs (NSAIDs) block the late, prostanoid-dependent/ceramide-independent component of ovarian IL-1 action: implications for the ovulatory process
    Ando, M
    Kol, S
    Irahara, M
    Sirois, J
    Adashi, EY
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1999, 157 (1-2) : 21 - 30
  • [3] [Anonymous], 1995, JAMA, V273, P491
  • [4] Barakat RR, 2000, CANCER, V89, P383, DOI 10.1002/1097-0142(20000715)89:2<383::AID-CNCR25>3.0.CO
  • [5] 2-T
  • [6] EFFECT OF DIFFERENTIATION AGENTS ON EXPRESSION OF CA-125, ALKALINE-PHOSPHATASE, AND CYTOKERATINS IN HUMAN OVARIAN ADENOCARCINOMA CELLS (OVCA-433)
    BROOKS, SE
    TIMMERMAN, J
    LAU, CC
    TSAO, SW
    KNAPP, RC
    SHEETS, EE
    [J]. GYNECOLOGIC ONCOLOGY, 1991, 42 (03) : 265 - 272
  • [7] RESPONSE OF 4 HUMAN OVARIAN-CARCINOMA CELL-LINES TO ALL-TRANS-RETINOIC ACID - RELATIONSHIP WITH INDUCTION OF DIFFERENTIATION AND RETINOIC ACID RECEPTOR EXPRESSION
    CALIARO, MJ
    MARMOUGET, C
    GUICHARD, S
    MAZARS, P
    VALETTE, A
    MOISAND, A
    BUGAT, R
    JOZAN, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) : 743 - 748
  • [8] *CANC STER HORM ST, 1987, NEW ENGL J MED, V316, P650, DOI DOI 10.1056/NEJM198703123161102
  • [9] Cornelison TL, 1997, CANCER DETECT PREV, V21, P1
  • [10] FACTORS AFFECTING THE ASSOCIATION OF ORAL-CONTRACEPTIVES AND OVARIAN-CANCER
    CRAMER, DW
    HUTCHISON, GB
    WELCH, WR
    SCULLY, RE
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (17) : 1047 - 1051